New Nordic Healthbrands AB (publ) Nine Months Report Q3 2014 Janury-September

|  | NINE MONTHS | NINE MONTHS | Q3 | Q3 |
| :---: | :---: | :---: | :---: | :---: |
|  | 2014 | 2013 | 2014 | 2013 |
| Net sales, kSEK | 201256 | 168292 | 65249 | 58337 |
| Gross profit, kSEK | 128800 | 111748 | 40911 | 36066 |
| Gross margin, \% | 64,0 | 66.4 | 62,7 | 61.8 |
| EBITDA, kSEK | 14185 | 11034 | 5768 | 3945 |
| EBITDA, \% | 7.0 | 6.6 | 8.8 | 6.8 |
| Operating profit, kSEK | 12192 | 8777 | 5131 | 3194 |
| Operating margin, \% | 6.1 | 5.2 | 7.9 | 5.5 |
| Profit for the period, kSEK | 9221 | 4625 | 4259 | 1108 |
| Earnings per share*, SEK | 1.49 | 0.75 | 0.69 | 0.18 |
| EBITDA per share, SEK | 2.29 | 1.78 | 0.93 | 0.64 |

*There are no dilutive effects

## Comments by CEO

Sales and earnings continued to grow in the third quarter as we get more and more loyal consumers.
Revenues grew nearly 13 percent in local currencies during the first 9 months of the year. After translation to Swedish kronor, sales amounted to a record 201,3 million SEK. A growth of 19 percent.

The growth is fueled by increasing marketing efforts, a focus on close and dynamic cooperation with retailers and the introduction of new product innovations and variants.

The biggest absolute growth has come from European countries outside the Nordic area, followed by North America and then the Nordic area.

The Nordic area now accounts for 44 percent of sales and contributes with around 50 percent of our total profit. The other geographic areas are also contributing to our profit, but they are still burdened with heavy investments in marketing in order to gain more loyal consumers and international market share. Sales in USA are also growing but the profit from the USA operation is still insignificant.

We experience increasing interest from reputable national and regional companies around the world, who are interested in representing New Nordic in their own market. Already last year we began a fruifful cooperation with IceCare in Island and this cooperation has developed very well. Recently we also entered a distribution agreement with Omega Pharma who started to sell New Nordic in Benelux as from October 2014.

The gross margin amounted to 64.0 percent in the first nine months. It is a decrease compared to same period last year. In the 3rd quarter the gross margin amounted to 62.7 percent which is an improvement compared with same quarter last year. The gross margin in the quarter has been influenced by unusual disposal of expired items on stock. During the year, the gross margin has been under pressure because of higher demands from retailers to give discounts. A trend that we will take efforts to change. We plan to reach a gross margin of minimum 65 percent in the next few years through different means.

The marketing efforts has been effective and the cost control satisfactory, with a further decrease of staff and administrative expenses as a percentage of sales. We therefore managed to increase the EBITDA by 28 percent to 14.2 million SEK in the nine months period. This is an EBITDA of 7 percent of sales.

Our ambitions are higher, but it is a fine improvement from same period last year and a step in the right direction. The sales of 5.4 million SEK and gross profit of 3.5 million SEK per employee in just nine months bear witness to an effective administration and organization.

Several new products are in the pipeline for 2015 and we continue to build our herbal know how. The clinical "Napoli" study on our Zuccarin® tablet (known in Scandinavia as Mulberry ${ }^{\top M}$ ) has been published recently. The study showed that people on a 1300 calorie restricted diet lose up to 3 times more weight ( 9 kg in 3 months) than those just following the 1300 kcal per day diet and taking a placebo tablet. An extraordinary good result, which strengthen the scientific understanding of this unique tablet. Beyond building a know how within the company it is equally important to convey this know how outside New Nordic. Therefore, it has been a great pleasure to see the positive response we have received from external health advisors and retail staff who participated in our new training program "Herbal Workshop". A program that we are going to continue in the future.

The internationalization of New Nordic continues in a good momentum. We are taking market share in the growing international food supplement market. We want to increase our international sales hand in hand with increasing our profitabil-
ity and earnings per share. The efficacy of our marketing efforts, our capabilities of increasing the gross margin, and the success of our new product introductions will be crucial to our results.

We will continue to increase marketing spend for our established products and invest in new brands.
I am full of optimism and looking forward to an exciting and rewarding year for the New Nordic and our shareholders.

## Karl Kristian Bergman Jensen

## Turnover

Sales for the first nine months was 201,3 million (168.3), an increase of 19 percent. In local currencies, the increase was 13 percent.

## Results for the nine months

Gross profit for the first nine months amounted to SEK 128.8 million (111.7). This corresponds to a gross margin of 64.0 percent (66.4). EBITDA amounted to SEK 14.2 million (11.0). This corresponds to an EBITDA margin of 7.0 percent (6.6).

Operating income amounted to SEK 12.2 M (8.8). This corresponds to an operating margin of 6.1 percent (5.2).
Profit after financial items amounted to SEK 12.1 million (7.3).
Profit after tax for the nine months amounted to 9.2 million (4.6).

## Comments for third quarter

Sales in local currencies increased by 3 percent. Converted into SEK, sales rose 11 percent. EBITDA increased by 1.8 million and net income of 3.2 million.
Gross margin increased to 62.7 percent (61.8). Selling and administrative expenses amounted to SEK 35.1 million (32.1), an increase of 9 percent.
Profit after financial items amounted to SEK 5.2 million (2.5).
Inventories increased by 6 percent compared to the same period last year and amounted to SEK 31.2 M (29.4). The balance sheet increased with 4 percent compared with the same period last year and amounted to SEK 96.9 M (92.9).

## Financial position and cash flow

Total assets as at 30 September 2014 amounted to SEK $96.9 \mathrm{M}(92,9)$, an increase of 4 percent compared to the same time last year. Intangible assets are amortized at the end of the period to SEK 3.7 M (5.8).
Operating activities generated a positive cash flow of SEK $4.8 \mathrm{M}(0.3)$ during the first nine months. Cash and cash equivalents amounted to MSEK 5.4 (7.6).
The Group's equity ratio was 22.9 per cent (13.7).
Equity apportioned on the outstanding $6,195,200(6,195,200)$ shares at 30 September 2014 amounted to 3.59 SEK (2.06).

## Expansion

In 2014, the company will continue to focus on a narrow range facing the international emerging market categories. New Nordic expects to increase sales in all markets in which the company operates.

## Parent company

The parent company had in operation the first nine months of 2014 a turnover of SEK $81.6 \mathrm{M}(48.8)$.
The reason for the significant increase in sales during the period is that the parent company last year has taken over invoicing against its subsidiaries.

## Comment to this quarter

No particular comments regarding the current quarter.

## Transactions with related parties

There have been no material related party transactions during the period.

## Accounting principles

This report has been prepared in accordance with the Annual Accounts Act and the Financial Accounting Standards Council's recommendations.

## Certified advicer

New Nordic Health Brands AB's Certified Adviser, Mangold Fondkommission AB.
Phone: +46 8-503 01550

## Future reports

| 6th March, 2015 | Full Year Report 2014 |
| :--- | :--- |
| 14th April, 2015 | Annual Report 2014 |
| 29th April, 2015 | Three Month Report 2015 |
| 29th April, 2015 | General Meeting 2015 |
| 31th July, 2015 | Six Months Report, 2015 |
| 30th October, 2015 | Nine Months Report, 2015 |

For further information contact: Karl Kristian Bergman Jensen, CEO, kk@newnordic.com
This report has not been audited.

Malmö October 31, 2014
New Nordic Health Brands $A B$ (publ)

New Nordic Health Brands AB
Södra Förstadsgatan 3 • SE-211 43 Malmö, Sweden • Phone: +46 40236414

## Income Statement

| (kSEK) | NINE MONTHS 2014 | NINE MONTHS 2013 | Q3 2014 | Q3 2013 |
| :---: | :---: | :---: | :---: | :---: |
| Sales | 201256 | 168292 | 65249 | 58337 |
| Cost of goods sold | -72 456 | -56 544 | -24 338 | -22 271 |
| Gross profit | 128800 | 111748 | 40911 | 36066 |
| Personnel expenses | -19820 | -19 523 | -6 191 | -7 212 |
| Other external expenses | -94795 | -81 191 | -28952 | -24909 |
| EBITDA | 14185 | 11034 | 5768 | 3945 |
| Depreciations | -1993 | -2 257 | -637 | -751 |
| Operating profit (EBIT) | 12192 | 8777 | 5131 | 3194 |
| Interest and other financial items | -77 | -1477 | 32 | -724 |
| Profit after financial items | 12115 | 7300 | 5163 | 2470 |
| Tax | -2 894 | -2 675 | -904 | -1362 |
| Profit for the period | 9221 | 4625 | 4259 | 1108 |
| Average number of shares | 6195200 | 6195200 | 6195200 | 6195200 |
| Number of shares by the end of the period* | * 6195200 | 6195200 | 6195200 | 6195200 |
| Earnings per share, SEK | 1.49 | 0.75 | 0.69 | 0.18 |
| EBITDA per share, SEK | 2.29 | 1.78 | 0.93 | 0.64 |

*There are no dilutive effects

## Balance Sheet

| (kSEK) | Q3 2014 | Q3 2013 | ANNUAL 2013 |
| :---: | :---: | :---: | :---: |
| Assets |  |  |  |
| FIXED ASSETS |  |  |  |
| Intangible fixed assets | 3682 | 5809 | 5246 |
| Tangible fixed assets | 1938 | 1613 | 1514 |
| Financial assets | 10314 | 6478 | 6732 |
| Total fixed assets | 15934 | 13900 | 13492 |
| CURRENT ASSETS |  |  |  |
| Inventories | 31195 | 29397 | 30602 |
| Current receivables | 44419 | 42020 | 40122 |
| Liquid funds | 5357 | 7623 | 6072 |
| Total current assets | 80971 | 79040 | 76796 |
| Total assets | 96905 | 92940 | 90288 |
| Equity and liabilites |  |  |  |
| EQUITY | 22210 | 12740 | 13549 |
| Deffered tax | 3104 | 2745 | 1916 |
| Long-term debt | 1181 | 1684 | 785 |
| Short term liabilities - interest bearing | 6477 | 8094 | 10324 |
| Short term liabilities - non interest bearing | 63933 | 67677 | 63714 |
| Current liabilities | 70410 | 75771 | 74038 |
| TOTAL LIABILITIES AND EQUITY | 96905 | 92940 | 90288 |

## Change in Equity

Q3 2014

| (kSEK) | Share capital | Restricted reserves | Free equity | Total equity |
| :---: | :---: | :---: | :---: | :---: |
| Balance | 6195 | 3935 | 3419 | 13549 |
| Exchange rate differences | 0 | 0 | -560 | -560 |
| Profit for the period | 0 | 0 | 9221 | 9221 |
| Balance | 6195 | 3935 | 12080 | 22210 |

Q3 2013

| (kSEK) | Share capital | Restricted reserves | Free equity | Total equity |
| :---: | :---: | :---: | :---: | :---: |
| Balance | 6195 | 3165 | -888 | 8472 |
| Exchange rate differences | 0 | 0 | -357 | -357 |
| Profit for the period | 0 | 0 | 4625 | 4625 |
| Balance | 6195 | 3165 | 3380 | 12740 |

ANNUAL 2013

| (kSEK) Sh | Share capital | Restricted reserves | Free equity | Total equity |
| :---: | :---: | :---: | :---: | :---: |
| Balance | 6195 | 3165 | -888 | 8472 |
| Transfer between restricted and unrestricted reserves | es 0 | 770 | -770 | 0 |
| Exchange rate differences | 0 | 0 | -704 | -704 |
| Profit for the period | 0 | 0 | 5781 | 5781 |
| Balance | 6195 | 3935 | 3419 | 13549 |

## Cash Flow Statements

| (kSEK) | NINE MONTHS 2014 | NINE MONTHS 2013 | Q3 2014 | Q3 2013 |
| :---: | :---: | :---: | :---: | :---: |
| CURRENT OPERATIONS |  |  |  |  |
| Profit after financial items | 12192 | 8777 | 5131 | 3194 |
| Adjustments for |  |  |  |  |
| Depreciations | 1993 | 2257 | 637 | 751 |
| Other provisions | 3370 | 1651 | 1576 | 893 |
|  | 17555 | 12685 | 7344 | 4838 |
| Interest recieved | 189 | 253 | 69 | 77 |
| Interest expense | -1315 | -1730 | -430 | -801 |
| Taxation paid | -3 266 | -3 245 | -495 | -1 155 |
| Cash flow from current operations before changes in working capital | 13163 | 7963 | 6488 | 2959 |
| Cash flow from changes in working capital |  |  |  |  |
| Inventories | -2 081 | -472 | -252 | -725 |
| Current receivables | -279 | -3 438 | 7666 | 2635 |
| Current liabilities | -5969 | -3791 | -12 164 | -1585 |
| Cash flow from current operations | 4834 | 262 | 1738 | 3284 |
| INVESTMENT ACTIVITIES |  |  |  |  |
| Investment in intagible fixed assets | 0 | -31 | 0 | 0 |
| Investments in tangible fixed assets | -814 | -424 | -12 | -245 |
| Long term receivables | -3993 | 802 | -1293 | 274 |
| Cash flow from investment activities | -4807 | 347 | - 305 | 29 |
| FINANCING ACTIVITIES |  |  |  |  |
| Changes in long term debt | -938 | 1853 | -244 | 1072 |
| Cash flow from financing activities | -938 | 1853 | -244 | 1072 |
| Changes in liquid funds | -911 | 2462 | 189 | 4385 |
| Liquid funds at the beginning of the period | - 6072 | 5186 | 5084 | 3264 |
| Exchange rate effect | 196 | -25 | 84 | -26 |
| Liquid funds at the end of the period | 5357 | 7623 | 5357 | 7623 |

Key Figures

| (kSEK) | NINE MONTHS 2014 | NINE MONTHS 2013 | Q3 2014 | Q3 2013 |
| :---: | :---: | :---: | :---: | :---: |
| Sales | 201256 | 168292 | 65249 | 58337 |
| Gross profit | 128800 | 111748 | 40911 | 36066 |
| EBITDA | 14185 | 11034 | 5768 | 3945 |
| Operating profit | 12192 | 8777 | 5131 | 3194 |
| Profit after financial items | 12115 | 7300 | 5163 | 2470 |
| Total assets | 96905 | 92940 | 96905 | 92940 |
| Return on capital employed, \% | 41.5 | 40.1 | 17.9 | 14.4 |
| Return on shareholders equity, \% | 41.5 | 36.3 | 19.2 | 8.7 |
| Equity | 22210 | 12740 | 22210 | 12740 |
| Equity ratio, \% | 22.9 | 13.7 | 22.9 | 13.7 |
| Dept ratio | 3.36 | 6.3 | 3.36 | 6.3 |
| Interest coverage ratio | 46.5 | 5.2 | 140.54 | 4.08 |
| Investments | 814 | 455 | 12 | 245 |
| Cash flow from current operations | 4834 | 262 | 1738 | 3284 |
| Gross margin, \% | 64.0 | 66.4 | 62.7 | 61.8 |
| EBITDA margin, \% | 7.0 | 6.6 | 8.8 | 6.8 |
| Operation margin, \% | 6.1 | 5.2 | 7.9 | 5.5 |
| Profit margin, \% | 6,0 | 4.3 | 7.9 | 4.2 |
| Number of employees, average | 37 | 37 | 37 | 37 |
| Number of shares by the end of the period | 37 | 37 | 37 | 37 |
| Sales per employee | 5439 | 4548 | 1763 | 1577 |
| Gross margin per emplyee | 3481 | 3020 | 1106 | 975 |
| Profit per employee | 327 | 197 | 140 | 67 |
| Average number of shares in the period | 6195200 | 6195200 | 6195200 | 6195200 |
| Number of shares by the end of the period* | * 6195200 | 6195200 | 6195200 | 6195200 |
| EBITDA per share, SEK | 2.29 | 1.78 | 0.93 | 0.64 |
| Profit per share*, SEK | 1.49 | 0.75 | 0.69 | 0.18 |
| Equity per share, SEK | 3.59 | 2.06 | 3.59 | 2.06 |

[^0]
## New Nordic Geographic Segments

| Sales divided by gergraphic, SEK | Q3 2014 |  | Q3 2013 |  | ANNUAL 2013 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | MSEK | PROCENT | MSEK | PROCENT | MSEK | PROCENT |
| Nordic | 29 | 44 | 30 | 51 | 103 | 45 |
| Rest of Europe | 20 | 31 | 16 | 28 | 70 | 31 |
| North America | 14 | 22 | 10 | 18 | 48 | 21 |
| Rest of the World | 2 | 3 | 2 | 3 | 7 | 3 |

## Quarterly Overview

|  | 2014 |  |  | 2013 |  |  |  | 2012 |  |  |  | 2011 |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Q 1 | Q 2 | Q 3 | Q 1 | Q 2 | Q 3 | Q 4 | Q 1 | Q 2 | Q 3 | Q 4 | Q 1 | Q 2 | Q 3 | Q 4 |
| Turnover excl. VAT MSEK | 61.1 | 74.9 | 65.2 | 51.0 | 58.9 | 58.3 | 59.7 | 52.2 | 55.5 | 49.4 | 46.7 | 47,3 | 52,3 | 51,6 | 48,2 |
| Change from last year, \% | 19.7 | 27.2 | 11.8 | -2.2 | 6.1 | 18.0 | 27.8 | 10.2 | 6.1 | -4.3 | -3.2 | 2,7 | 4,1 | 10,6 | -7,8 |
| EBITDA, MSEK | 3.8 | 4.7 | 5.8 | 3.5 | 3.6 | 3.9 | 1.1 | 3.3 | 2.0 | 2.9 | -2.7 | 3.1 | 4.1 | 6.1 | 0.8 |
| EBITDA-margin, \% | 6.1 | 6.2 | 8.8 | 6.8 | 6.1 | 6.8 | 1.9 | 6.4 | 3.5 | 5.8 | -5.7 | 6.5 | 7.9 | 11.7 | 1.7 |
| Operating result, MSEK | 3.1 | 4.0 | 5.1 | 2.7 | 2.9 | 3.2 | 0.4 | 1.4 | 0.0 | 1.0 | -3.4 | 1.1 | 2.2 | 4.1 | -1.4 |
| Operating margin, \% | 5.1 | 5.3 | 7.9 | 5.3 | 4.9 | 5.5 | 0.6 | 2.7 | 0.1 | 1.9 | -7.4 | 2.3 | 4.2 | 7.9 | -2.8 |
| Result before tax, MSEK | 2.7 | 4,2 | 5.2 | 1.9 | 2.9 | 2.5 | 0.6 | 0.7 | -1.0 | -0.3 | -4.1 | 0.3 | 1.3 | 4.0 | -3.2 |
| Result after tax, MSEK | 2.1 | 2,9 | 4.3 | 1.3 | 2.2 | 1.1 | 1.2 | 0.5 | -0.8 | -0.8 | -3.0 | 0.2 | 1.6 | 1.1 | -2.6 |
| Cash, MSEK | 4.9 | 5.1 | 5.4 | 3.9 | 3.3 | 7.6 | 6.1 | 2.0 | 2.2 | 4.5 | 5.2 | 1.0 | 1.8 | 2.6 | 1.5 |
| Stocks, MSEK | 30.4 | 32.2 | 31.2 | 29.9 | 30.1 | 29.4 | 30.6 | 27.8 | 30.7 | 28.8 | 31.1 | 26.8 | 28.8 | 22.2 | 26.9 |
| Equity, MSEK | 15.7 | 18.2 | 22.2 | 9.7 | 11.8 | 12.7 | 13.5 | 12.2 | 11.3 | 11.4 | 8.5 | 12.9 | 14.3 | 15.2 | 11.6 |
| Result per share, SEK | 0.33 | 0.47 | 0.69 | 0.20 | 0.36 | 0.18 | 0.19 | 0.08 | -0.12 | -0.14 | -0.49 | 0.03 | 0.27 | 0.17 | -0.42 |
| Equity per share, SEK | 2.54 | 2.95 | 3.59 | 1.57 | 1.90 | 2.06 | 2.19 | 1.96 | 1.82 | 1.85 | 1.37 | 2.08 | 2.31 | 2.46 | 1.88 |
| Cash flow per share, SEK | 0.34 | 0.16 | 0.28 | -0.24 | -0.13 | 0.53 | -0.09 | 0.29 | 0.01 | 0.39 | -0.10 | 0.10 | 0.27 | 0.45 | -0.59 |
| Solidity, \% | 16.8 | 17.6 | 22.9 | 11.1 | 12.7 | 13.7 | 15.0 | 12.6 | 11.5 | 12.7 | 9.2 | 12.4 | 12.9 | 15 | 12.3 |

Gross profit: New Nordic's gross profit is the company's net sales less costs to New Nordic suppliers.
Equity: Equity as a percentage of total assets.
Leverage ratio: The ratio of total liabilities and equity.
Profit margin: Profit after financial items plus financial expenses divided by financial expenses.
Return on equity: Net income as a percentage of shareholders' equity at period end.
Capital employed: Total assets less non-interest-bearing provisions and liabilities.
Return on capital employed: Profit after financial items
plus financial expenses divided by capital employed.
Investments: Investments in tangible and intangible assets.
Gross margin: Gross profit as a percentage of net sales.
EBITDA margin: Operating income before depreciation and amortization as a percentage of net sales.
Operating margin: Operating profit after depreciation and amortization as a percentage of net sales.
Profit margin: Profit after financial items as a percentage of net sales.
Revenue per employee: Net sales divided by the average number of employees.
Gross profit per employee: Gross profit divided by the average number of employees.
Profit per employee: Profit after financial items divided by the average number of employees.
Earnings per share: Profit after tax divided by the average number of shares.
Equity per share: Shareholders' equity divided by shares outstanding at period end.


[^0]:    *There are no dilutive effects

